Skip to main content
. Author manuscript; available in PMC: 2014 Apr 10.
Published in final edited form as: J Nucl Med. 2012 Aug 23;53(10):1592–1600. doi: 10.2967/jnumed.111.102293

TABLE 1.

Comparison of tumor to muscle ratios of 89Zr-df-Onartuzumab and 76Br-Onartuzumab in MKN-45 xenografts from 6 h to 120 h.

Tumor to muscle ratios*
Time of Uptake (h) 6 18 24 48 72 96 120
89Zr-df-Onartuzumab -- 6.4
(0.4)
7.1
(1.0)
13.2
(2.4)
12.2
(2.3)
19.6
(2.4)
26.6
(0.9)
76Br-Onartuzumab 3.7
(0.4)
3.8
(0.4)
4.5
(0.9)
5.8
(0.7)
5.3
(0.6)
-- --
*

Each value represents the mean ratio with the standard deviation below in parenthesis; n= 5.